EZH2 and metastatic neoplasm: Our observations add to this growing field by indicating that dysregulated promoter recruitment of EZH2 to CIITApIV also occurs in MDAMB 435 variants and further indicates EZH2 as a primary culprit in metastatic tumor growth.